4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Triggerable nanomaterials to modulate cell activity (NanoTrigger)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,
The advent of molecular reprogramming and the associated opportunities for personalised and therapeutic medicine requires the development of novel systems for on-demand delivery of reprogramming factors into cells in order to modulate their activity/identity. Such triggerable systems should allow precise control of the timing, duration, magnitude and spatial release of the reprogramming factors. F ...
Voir le projet
1
Participant partenaire
TERMINÉ
Cancer Associated Fibroblasts (CAF) Function in Tumor Expansion and Invasion (CAFFEIN)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2016,
"Aim of the CAFFEIN network is to provide 10 early stage researchers (ESRs) and 2 exprerienced researchers (ERs) with excellent training in an industry relevant area of cancer research, complementary skills required for pharmaceutical industry, and knowledge in setting up biomedical start-up companies. To this end, the network comprises two full industrial partners: the established pharmaceutical ...
Voir le projet
11
Participants partenaires
TERMINÉ
TreatPolyQ – Industrial Academic Initial Training Network towards treatment of Polyglutamine Diseases (TREATPOLYQ)
Date du début: 1 mars 2011, Date de fin: 28 févr. 2015,
Protein aggregation is a hallmark of many late onset neurodegenerative disorders including Parkinson’s Disease (PD), Alzheimer’s Disease (AD), amyotrophic lateral sclerosis (ALS), prion diseases as well as the group of polyglutamine diseases (polyQ). The aim of this proposal is to create a network of European partners bridging important basic mechanisms involved in proteinopathies, research of mod ...
Voir le projet
17
Participants partenaires
TERMINÉ
The role of reactive oxygen species in B cell tolerization and immune memory (BNOX)
Date du début: 1 juin 2009, Date de fin: 31 mai 2012,
"Chronic inflammation is a common feature in diseases like primary immunodeficiencies and autoimmunity. It is the consequence of the inability of the immune system to regulate and resolve the inflammatory process. Even though significant advances have been made in the past years to understand some of the mechanisms involved in chronic inflammation, which lead to the development of therapeutic stra ...
Voir le projet